N4 Pharma Plc is a UK-based specialist pharmaceutical company that focuses on the development of a silica nanoparticle delivery system for pharmaceutical and biotech companies. Its flagship product, Nuvec, is a non-viral adjuvant delivery system that is designed to enhance the efficacy of vaccines and cancer treatments. The company has a research partnership with Nanomerics Limited to develop different formulations of Nuvec. N4 Pharma was founded in 1979 and is headquartered in London, UK.